Definition & nosological framework

The corneal endothelium is a monolayer of hexagonal cells lining the posterior cornea that keeps it transparent by pumping water out of the stroma. This population is post-mitotic: born in finite number (~4,000–5,000 cells/mm² at birth), it declines with age, and any loss is compensated not by division but by spreading of neighbouring cells (polymegathism, pleomorphism).

Cornea guttata refers to focal excrescences on the posterior Descemet membrane — the guttae — secreted by a distressed endothelium. Isolated and asymptomatic, it may be only an examination sign. When it is associated with progressive, symptomatic endothelial rarefaction leading to corneal edema, it defines Fuchs endothelial corneal dystrophy (FECD) — the leading indication for endothelial keratoplasty in Western countries. The disease is bilateral, often asymmetric, female-predominant, and typically presents after the fifth decade in its late-onset form, by far the most common.

Pathophysiology

The whole disease lies in the failure of a dual endothelial function: an active pump (Na⁺/K⁺-ATPase, evacuating stromal water) and a barrier (tight junctions, limiting aqueous inflow). While cell density is sufficient, balance holds; below a critical threshold (a few hundred cells/mm²), the pump no longer offsets the leak and water accumulates.

Cascade. Endothelial rarefaction and guttae compromise the pump: water first invades the stroma (which thickens), then the epithelium, raising painful bullae (bullous keratopathy). Descemet thickens through deposition of an abnormal posterior collagenous layer (ultrastructural banded then non-banded layers).

Upstream of this mechanical failure, several molecular mechanisms converge toward cell death. Oxidative stress is central: a highly active post-mitotic tissue, the endothelium accumulates reactive oxygen species, its anti-oxidant defences (including Nrf2) are overwhelmed, with mitochondrial DNA damage and apoptosis. The female predominance is explained here: estrogen metabolism produces, via CYP1B1, catechol metabolites (4-hydroxy-estradiol) and quinones that form DNA adducts; detoxifying enzymes (NQO1, COMT) are deficient in FECD, and UVA exposure potentiates the process. Add endoplasmic reticulum stress (UPR, protein misfolding) and defective quality-control pathways (autophagy). The result is a disease of proteostasis and oxidative stress destroying a tissue that cannot regenerate.

Genetics

FECD is genetically heterogeneous, most often autosomal dominant with variable penetrance, with polygenic and environmental components. One determinant dominates: expansion of the CTG18.1 trinucleotide repeat in an intron of TCF4, associated with the majority of late-onset cases in populations of European ancestry. The pathogenic threshold is around ≥ 40 repeats; the mechanism is not simple loss of function but RNA toxicity: the repeat-bearing RNA forms nuclear foci that sequester splicing factors (MBNL1), causing toxic mis-splicing — a model close to myotonic dystrophy.

Beside this principal actor, several genes account for rarer or earlier forms: COL8A2 (early-onset, Descemet collagen VIII), SLC4A11, ZEB1 (also implicated in posterior polymorphous dystrophy), AGBL1 and LOXHD1. In practice genotyping is not required for diagnosis (clinical); it informs family counselling and, with the TCF4 repeat, opens targeted therapeutic avenues — antisense oligonucleotides (ASO) and small molecules dissolving the RNA foci, or CRISPR correction, currently preclinical.